ICML 2023 | Tafasitamab-lenalidomide in R/R DLBCL: clinical trial results and real-world data
Gabriel Brisou
• 14 Jun 2023
In this video, Gabriel Brisou, MD, Centre d’Immunologie de Marseille-Luminy (CIML), Marseille, France, discusses treatment options emerging for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for CAR-T cells, drawing focus on the combination of tafasitamab and lenalidomide. Dr Brisou summarizes findings from the L-MIND trial (NCT02399085), and compares this to real-world data (RWD) obtained with the use of this regimen. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
